Evidence map›Paper›PMID 32454997›Full record

ArticleCardiology research and practice2020

Decreased Mortality with Beta-Blocker Therapy in HFpEF Patients Associated with Atrial Fibrillation.

Yanhua Yang, Suxia Guo, Ziyao Huang, Chunhua Deng, Lihua Chen, Guoxiang Zhou, Zhengwei Jian, Ruping He, Zhichao Huang, Yongzhao Yao and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiology research and practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yanhua YangDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Suxia GuoDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.ORCID https://orcid.org/0000-0001-7704-2522
Ziyao HuangDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Chunhua DengDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Lihua ChenDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Guoxiang ZhouDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Zhengwei JianDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Ruping HeDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Zhichao HuangDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Yongzhao YaoDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Jiongbin LuDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Zhiwen HuaDepartment of Cardiology, Affiliated Dongguan People's Hospital, Southern Medical University, No. 3, South Wandao Road, Wanjiang District, Dongguan, Guangdong Province 523059, China.
Yuli HuangDepartment of Cardiology, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, China.ORCID https://orcid.org/0000-0001-5104-567X
Dongguan People’s Hospital · CNThe First People's Hospital of Shunde · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are no proven effective treatments that can reduce the mortality in heart failure with preserved ejection fraction (HFpEF), probably due to its heterogeneous nature which will weaken the effect of therapy in clinical studies. We evaluated the effect of beta-blocker treatment in HFpEF patients associated with atrial fibrillation (AF), which is a homogeneous syndrome and has seldom been discussed.

methodsThis retrospective cohort study screened 955 patients diagnosed with AF and HFpEF. Patients with a range of underlying heart diseases or severe comorbidities were excluded; 191 patients were included and classified as with or without beta-blocker treatment at baseline. The primary outcome was all-cause mortality and rehospitalization due to heart failure. Kaplan-Meier curves and multivariable Cox proportional-hazards models were used to evaluate the differences in outcomes.

resultsThe mean follow-up was 49 months. After adjustment for multiple clinical risk factors and biomarkers for prognosis in heart failure, patients with beta-blocker treatment were associated with significantly lower all-cause mortality (hazard ratio (HR) = 0.405, 95% confidence interval (CI) = 0.233-0.701,

conclusionsIn HFpEF patients associated with AF, beta-blocker treatment is associated with significantly lower all-cause mortality, but it increased the risk of rehospitalization due to heart failure.

Identifiers

PMID32454997
PMCPMC7243006
OpenAlexW3025805184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.